Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 9/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391452 | 1.00 | AAK1 (0.53) | AAK1LNPEPERAP2HDAC1KDM4E | |
| SCHEMBL12433335 | 0.89 | AAK1 (0.54) | AAK1LNPEPERAP2 | |
| SCHEMBL1390928 | 0.87 | KDM4E (0.48) | AAK1LNPEPERAP2HDAC1KDM4E | |
| SCHEMBL1390927 | 0.87 | KDM4E (0.48) | AAK1LNPEPERAP2HDAC1KDM4E | |
| SCHEMBL16709740 | 0.86 | KDM4E (0.47) | AAK1LNPEPERAP2KDM4EALDH1A1 | |
| SCHEMBL6296452 | 0.86 | AAK1 (0.74) | AAK1LNPEPERAP2HDAC1 | |
| SCHEMBL1390543 | 0.85 | KDM4E (0.45) | AAK1LNPEPERAP2KDM4EALDH1A1 | |
| SCHEMBL1390542 | 0.85 | KDM4E (0.45) | AAK1LNPEPERAP2KDM4EALDH1A1 | |
| SCHEMBL1206766 | 0.84 | LNPEP (0.59) | AAK1LNPEPERAP2HDAC1KDM4E | |
| SCHEMBL13497769 | 0.83 | KDM4E (0.46) | AAK1LNPEPERAP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | AAK1 415/4885LNPEP 3257/4885ERAP2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.